Unique ID issued by UMIN | UMIN000013231 |
---|---|
Receipt number | R000015440 |
Scientific Title | The effect of the cognitive function and cerebral white matter lesions of pitavastatin in hypercholesterolemic patients with cognitive dysfunction. |
Date of disclosure of the study information | 2014/03/01 |
Last modified on | 2017/07/05 12:11:22 |
The effect of the cognitive function and cerebral white matter lesions of pitavastatin in hypercholesterolemic patients with cognitive dysfunction.
the effect on the cognitive function and cerebral white matter lesions of pitavastatin in hypercholesterolemic patients with cognitive dysfunction
The effect of the cognitive function and cerebral white matter lesions of pitavastatin in hypercholesterolemic patients with cognitive dysfunction.
the effect on the cognitive function and cerebral white matter lesions of pitavastatin in hypercholesterolemic patients with cognitive dysfunction
Japan |
Hypercholesterolemic patients with cognitive dysfunction
Geriatrics |
Others
NO
To investigate the effect on cognitive function and cerebral white matter lesions of pitavastatin in hyperlipidemic patients with cognitive dysfunction.
Efficacy
.Change of cerebral white matter lesions(MRI)
.Change of arteriosclerosis marker(PWV, IMT)
.Change of cognitive function(MMSE)
.Change of cerebral blood flow(SPECT)
.Change of serum lipids
Interventional
Parallel
Non-randomized
Open -no one is blinded
Historical
2
Treatment
Medicine |
Pitavastatin Calcium(LIVALO) Taking a dose of 1-4mg once daily.
Daily dose is determined based on Japan Atherosclerosis Society Guidelines 2012 for Prevension of Atherosclerotic Cardiovascular Diseases.
Patients aged 75 years and over aim at less than LDL -C levels 140 mg/dL.
untreated group
65 | years-old | <= |
Not applicable |
Male and Female
1.Outpatients of Kyorin University Hospital Amnesia Center Judged that a lipid-lower therapy is required by Japan Atherosclerosis Society Guidelines 2012 for Prevention of Atherosclerotic Cardiovascular Diseases over 65 years old.
2.Patients who receive any statin can entry after 4 weeks washout periods.
3.the mild cognitive impairment to dementia patients.(15<=MMSE<=30)
4.PVH grade >=1/4 or DWMH grade >=1/4 (judged by two or more doctors)
5.Written informed consent is obtained from subjects or their family relatives or legally acceptable representatives before entry.
1.History of hypersensitivity to any of the ingredients of the product.
2.Severe hepatic disorder or biliary atresia.
3.Receiving cyclosporine.
4.Patients receiving fibrates who also have laboratory evidence of abnormal renal function.
5.Individuals who are ineligible in the opinion of the physician in charge.
60
1st name | |
Middle name | |
Last name | Koichi Kozaki |
Kyorin University School of Medicine
Department of Geriatric Medicine
6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
0422-47-5511
kourei@ks.kyorin-u.ac.jp
1st name | |
Middle name | |
Last name | Yukiko Moriya |
Kyorin University School of Medicine
Department of Geriatric Medicine
6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
0422-47-5511
m-yukiko@rk9.so-net.ne.jp
Department of Geriatric Medicine, Kyorin University School of Medicine
None
Self funding
NO
杏林大学医学部付属病院(東京都)
2014 | Year | 03 | Month | 01 | Day |
Unpublished
Completed
2013 | Year | 12 | Month | 01 | Day |
2014 | Year | 03 | Month | 01 | Day |
2016 | Year | 03 | Month | 31 | Day |
2014 | Year | 02 | Month | 23 | Day |
2017 | Year | 07 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015440